Ischemic heart disease associated with arterial hypertension is characterized by a high risk of cardiovascular complications and progression of atherosclerotic vascular damage. In recent years, systemic inflammation and immune dysregulation have been recognized as key pathogenetic mechanisms contributing to endothelial dysfunction and adverse cardiovascular remodeling. However, the effectiveness of immunocorrective therapy in modulating inflammatory and cytokine responses in this patient population remains insufficiently studied.